Stockholm 17:30
+0,59% Idag
+27,86% Sedan årsskifte
-0,01% OMXSPI

2019-06-25 08:00:00

Xvivo Perfusion: XVIVO Perfusion changes the date of reporting of the Report on Operations 2019 to January 30, 2020

XVIVO Perfusion AB (publ) has decided to change the date of reporting of the Report on Operations 2019 to January 30, 2020.

June 25, 2019

Magnus Nilsson, CEO

XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, +46 735 192159,
Magnus Nilsson, CEO, +46 31 788 2150,
For further information on XVIVO Perfusion's business, please refer to the company's website,

This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 am CET on June 25, 2019.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB (publ) is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.

The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.

Attached html: HTML
Attached pdf: PDF